Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients (Q36122842)

12 August 2017

1 reference

title

Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients (English)

1 reference

12 August 2017

Mark A Moyad

1

1 reference

12 August 2017

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

23

1 reference

12 August 2017

1

1 reference

12 August 2017

56-64

1 reference

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

The influence of androgen deprivation therapy on metabolism in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Osteoporosis and obesity in men receiving hormone therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Lifestyle recommendations to prevent prostate cancer, part I: time to redirect our attention?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Lifestyle recommendations to prevent prostate cancer, part II: time to redirect our attention?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Fruit and vegetable intake and risk of major chronic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Herbal medicines and perioperative care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Complementary and alternative medicine use by patients enrolled onto phase I clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Herbal remedies in the United States: potential adverse interactions with anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Selenium and vitamin E supplements for prostate cancer: evidence or embellishment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Improving overall men's health and potentially reducing the risk of certain cancers via serum markers and risk assessment for coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Cancer surpasses heart disease as leading cause of death for all but the very elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

C-reactive protein levels and outcomes after statin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

C-reactive protein and the risk of incident colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Homocysteine levels and the risk of osteoporotic fracture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Homocysteine as a predictive factor for hip fracture in older persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Effects of exercise training on older patients with major depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Hot flashes: aetiology and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

The impact of osteoporosis in men treated for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Preventing male osteoporosis: prevalence, risks, diagnosis and imaging tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Effect of Vitamin D on falls: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

Homocysteine: is it a clinically important cardiovascular risk factor?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

inferred from DOI database lookup

7 January 2021

based on heuristic

Treatment options for menopausal hot flashes

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.018

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLONC.2005.03.018

1 reference

12 August 2017

1 reference

PubMed ID

15885584